PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23603979-3	2013	METHODS: PC12 cells overexpressing either wild-type or A30P mutant alpha-synuclein were treated with the proteasome inhibitor epoxomicin, the macroautophagy inhibitor 3-MA and the macroautophagy activator rapamycin alone or in combination.	epoxomicin	126-136	synuclein alpha	Rattus norvegicus	67-82	
23603979-7	2013	RESULTS: When the proteasome and macroautophagy in the wild-type and mutant cells were inhibited with epoxomicin and 3-MA, respectively, the cell viability was significantly decreased, and the alpha-synuclein level was increased.	epoxomicin	102-112	synuclein alpha	Rattus norvegicus	193-208	
23603979-11	2013	Macroautophagy inducer rapamycin increased the cell viability and reduced epoxomicin-induced alpha-synuclein accumulation.	epoxomicin	74-84	synuclein alpha	Rattus norvegicus	93-108	
28619113-10	2017	Experiments with epoxomicin and chloroquine showed that proteasomal targeting of insoluble Ser129-phosphorylated alpha-synuclein was enhanced under lysosome inhibition and it reduced accumulation of insoluble total alpha-synuclein.	epoxomicin	17-27	synuclein alpha	Rattus norvegicus	113-128